Publicaciones científicas

Secondary myelodysplastic syndrome after treatment for promyelocytic leukemia: clinical and genetic features of two cases

Panizo C, Patiño A, Lecumberri R, Calasanz MJ, Odero MD, Bendandi M, Rocha E.
Department of Hematology, University Clinic of Navarra, University of Navarra, Navarra, Spain.

Revista: Cancer Genetics and Cytogenetics

Fecha: 01-sep-2003

Área de Terapia Celular Unidad de Genética Clínica Hematología y Hemoterapia

Acute promyelocytic leukemia (APL) represents a biologic and clinically well-defined subtype of acute nonlymphocytic leukemia with specific morphologic and karyotypic characteristics.

Although secondary leukemia and myelodysplastic syndromes (MDS) are the most frequent secondary neoplasms following chemotherapy for acute leukemia, their development after complete remission in patients with APL is uncommon. We describe the clinical and genetic features of two APL patients who achieved CR after chemotherapy and all-trans retinoid acid treatment and subsequently developed a MDS. Therapy-related MDS karyotype changes such as abnormalities of chromosomes 5 and 7 were found in the cytogenetic analysis.

Since TP53 alteration was detected in one case, possible implications of these findings in the onset of MDS are discussed.

CITA DEL ARTÍCULO  Cancer Genet Cytogenet. 2003 Jun;143(2):178-81



La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra


Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra


Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra